GlassScriptPhysician profile
Stephen Earl Ames
NPI 1467027805
$655.47
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $420 · Food and Beverage: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $420.00 |
| Food and Beverage | $235.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $420.00 | 2024 | Besremi |
| Novo Nordisk INC | $82.26 | 2024 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $37.92 | 2024 | Dexcom G6 Transmitter |
| Amgen INC. | $34.08 | 2024 | Otezla, Repatha, Evenity |
| Merck Sharp & Dohme LLC | $22.45 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Pfizer INC. | $21.67 | 2024 | |
| Astellas Pharma US INC | $20.95 | 2024 | Veozah |
| Lilly USA, LLC | $16.14 | 2024 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Ames listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.